JP2022514786A5 - - Google Patents

Info

Publication number
JP2022514786A5
JP2022514786A5 JP2021536253A JP2021536253A JP2022514786A5 JP 2022514786 A5 JP2022514786 A5 JP 2022514786A5 JP 2021536253 A JP2021536253 A JP 2021536253A JP 2021536253 A JP2021536253 A JP 2021536253A JP 2022514786 A5 JP2022514786 A5 JP 2022514786A5
Authority
JP
Japan
Prior art keywords
antibody
cdr2
cdr1
cdr3
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514786A (ja
JP7578289B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067457 external-priority patent/WO2020132232A2/en
Publication of JP2022514786A publication Critical patent/JP2022514786A/ja
Publication of JP2022514786A5 publication Critical patent/JP2022514786A5/ja
Priority to JP2024181493A priority Critical patent/JP7882548B2/ja
Application granted granted Critical
Publication of JP7578289B2 publication Critical patent/JP7578289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536253A 2018-12-21 2019-12-19 Muc18に特異的な抗体 Active JP7578289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024181493A JP7882548B2 (ja) 2018-12-21 2024-10-17 Muc18に特異的な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/122572 2018-12-21
CN2018122572 2018-12-21
PCT/US2019/067457 WO2020132232A2 (en) 2018-12-21 2019-12-19 Antibodies specific to muc18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024181493A Division JP7882548B2 (ja) 2018-12-21 2024-10-17 Muc18に特異的な抗体

Publications (3)

Publication Number Publication Date
JP2022514786A JP2022514786A (ja) 2022-02-15
JP2022514786A5 true JP2022514786A5 (cg-RX-API-DMAC7.html) 2022-12-16
JP7578289B2 JP7578289B2 (ja) 2024-11-06

Family

ID=71101906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536253A Active JP7578289B2 (ja) 2018-12-21 2019-12-19 Muc18に特異的な抗体
JP2024181493A Active JP7882548B2 (ja) 2018-12-21 2024-10-17 Muc18に特異的な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024181493A Active JP7882548B2 (ja) 2018-12-21 2024-10-17 Muc18に特異的な抗体

Country Status (7)

Country Link
US (2) US12364770B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898964A4 (cg-RX-API-DMAC7.html)
JP (2) JP7578289B2 (cg-RX-API-DMAC7.html)
CN (2) CN117343187A (cg-RX-API-DMAC7.html)
AU (2) AU2019401657B2 (cg-RX-API-DMAC7.html)
TW (2) TW202519555A (cg-RX-API-DMAC7.html)
WO (1) WO2020132232A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI851634B (zh) 2018-12-21 2024-08-11 大陸商沐特圖公司 Muc18特異性抗體
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824995B1 (en) * 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
EP1467756A4 (en) * 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
EP1470146B8 (en) * 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
CN105732813A (zh) * 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
CN102936283B (zh) * 2008-01-31 2014-11-05 中国科学院生物物理研究所 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法
US8679500B2 (en) 2009-05-14 2014-03-25 Institute National De La Sante Et De La Recherche Medicale (Inserm) Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related diseases
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
DK3049118T3 (en) * 2013-09-24 2018-08-13 Oncoinvent As MONOCLONAL ANTIBODY AND DERIVATIVES
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CN104650231A (zh) * 2015-02-13 2015-05-27 南京任诺药业有限公司 一种具备高效中和活性的人源化抗人cd146单克隆抗体
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) * 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018033630A1 (en) 2016-08-19 2018-02-22 Oncoinvent As Anti-osteosarcoma car-t derived from the antibody oi-3
WO2018220467A1 (en) 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
CN108129567B (zh) 2018-01-09 2019-02-26 南京任诺药业有限公司 一种具备高效中和活性的人源化抗人cd146单克隆抗体
TWI851634B (zh) 2018-12-21 2024-08-11 大陸商沐特圖公司 Muc18特異性抗體

Similar Documents

Publication Publication Date Title
JP2025026839A5 (cg-RX-API-DMAC7.html)
JP2021531825A5 (cg-RX-API-DMAC7.html)
JP2022523710A5 (cg-RX-API-DMAC7.html)
JP2021531826A5 (cg-RX-API-DMAC7.html)
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2023511774A5 (cg-RX-API-DMAC7.html)
JP2019511201A5 (cg-RX-API-DMAC7.html)
TW201734037A (zh) 多重專一性分子
JP2007526880A5 (cg-RX-API-DMAC7.html)
JP2020503870A5 (cg-RX-API-DMAC7.html)
JP2020530285A5 (cg-RX-API-DMAC7.html)
JP2023547323A5 (cg-RX-API-DMAC7.html)
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2019505564A5 (cg-RX-API-DMAC7.html)
JP2018503600A5 (cg-RX-API-DMAC7.html)
JP2022514693A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2020534012A5 (cg-RX-API-DMAC7.html)
JP2014515600A5 (cg-RX-API-DMAC7.html)
JP2020524669A (ja) 抗globo h抗体を含有する抗体−薬物コンジュゲートおよびその使用
WO2022060832A1 (en) Cd33 antibodies
CN117551200A (zh) 一种抗人cd45抗体或其抗原结合片段及其制备方法
CN115397857A (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途